Xiali ZHU,Linghua LI,Shasha WANG,Baiyan WANG,Yanbin GUAN,Yongyan JIA. Preparation and in vitro Antitumor Activity of Near-infrared Light Responsive Docetaxel Active Targeting Liposomes. 医药导报, 2021,40(8): 1094-1099.
Objective Using hydrophilic nano copper sulfide (PVP/CuS) as a photosensitizer,glycyrrhetinic acid (GA) as a tumor targeting molecule,docetaxel (DTX) as a model drug,a near-infrared light responsive active targeting liposomes (GA-DTX-PVP/CuS-Lip) was prepared,and its physical chemical properties and in vitro antitumor activity were also studied. Methods The thin film dispersion method was used to prepare GA-DTX-PVP/CuS-Lip,and its microstructure was observed under transmission electron microscope.The particle size and zeta potential were measured by laser granulometer.The encapsulation efficiency and drug loading ratio were determined using ultrafiltration and centrifugation method.Combined with 808 nm laser irradiation,the light-thermal conversion experiment was carried out.The in vitro drug release test was carried out by using the dialysis method at 37 ℃ and 45 ℃.The in vitro antitumor activity of GA-DTX-PVP/CuS-Lip against SMMC-7721 cells with or without 808 nm laser irradiation was also measured. Results GA-DTX-PVP/CuS-Lip was observed to be spherical with uniform size under TEM.The particle size and Zeta potential were (226.73±0.17) nm and (-4.05±0.57) mV,respectively.The encapsulation efficiency and drug loading ratio were (96.33±0.21) % and (6.63±0.39) %,respectively.GA-DTX-PVP/CuS-Lip had a significant photothermal conversion effect under laser irradiation at 808 nm in a concentration and time-dependent manner.The drug release test showed that compared with DTX solution,GA-DTX-PVP/CuS-Lip had sustained and temperature-dependent release characteristics,and the release rate at 45 ℃ was significantly higher than that at 37 ℃.GA-DTX-PVP/CuS-Lip had higher inhibitory effect on SMMC-7721 cells when combined with 808 nm laser irridation. Conclusion The preparation process of GA-DTX-PVP/CuS-Lip is stable and feasible,which can provide a theoretical basis for further tumor photothermal therapy.
Bingbing LIANG,Chengfei TANG,Juan HE,Huagang YAO. Pharmaceutical Study of Novel Azacyclocarbene Platinum (Ⅱ) Complexes on Antitumor Activity. 医药导报, 2021,40(6): 740-744.
Peng LIU,Zhaowen PENG,Xuan TU,Gaofei FENG,Kaiwen Hu. Exploration on A New Therapeutic Mode of the Combination of External Treatment of Traditional Chinese Medicine (TCM) and Argon-helium Cryoablation Under the Concept of 'Green Therapy' for Tumors. 医药导报, 2021,40(4): 482-486.
With the progress of diagnosis and treatment technology and drug research and development,the treatment methods of malignant tumors have been increasingly abundant.From empirical medicine to evidence-based medicine and from precision medicine to integrated medicine,the therapeutic mode of cancer is constantly upgraded.Traditional treatments would no longer meet the current needs completely.The immuno-targeted therapy,just being in the ascendant,is impacting the traditional three classic treatments,surgery,radiotherapy,and chemotherapy.Under the comprehensive treatment background,it is of great significance to explore an effective,low-toxic,low-damaging,and sustainable treatment mode,especially for advanced cancer.The 'green therapy' for tumors aims at maintaining patients' quality of life and modernizing the application of external therapies of traditional Chinese medicine (TCM). In combination with the guidance of Yin-Yang theory,argon-helium cryoablation,a minimally invasive treatment,can directly destroy the tumor with minimal side effects and effectively reduce side reactions of modern medical treatment at the same time,hence,achieving the dual effects of both and improving the quality of life and extending survival.In this paper,it reviews the concept of 'green therapy' of tumors and the associated researches,and further explores the new treatment mode of cancer with integrating traditional Chinese and Western medicines based on the real clinical cases and supporting the effectiveness of argon-helium cryoablation combined with TCM external therapies.
Xiulan LIU,Yi LIU,Lin QIU. Analysis of the Intervention of Pharmacist's Examining on the Irrational Medical Orders of Antineoplastic Drugs in PIVAS. 医药导报, 2021,40(10): 1423-1426.
Objective To analyze the irrational medical orders of anti-tumor drugs in pharmacy intravenous admixture services (PIVAS) and to evaluate the effect after the effective intervention,so as to standardize the rational use of clinical anti-tumor drugs. Methods The classification and statistical analysis of unreasonable chemotherapy prescriptions approved by the pharmacists in our hospital from January to June 2018 were analyzed,and the causes of irrational medical orders were explored and promptly intervened.The statistical analysis of data from July to December 2018 was carried out,and the effects of unreasonable medical intervention were evaluated.The methods and countermeasures for reducing irrational medical orders were summarized. Results In 2018,the proportion of irrational anti-tumor drug uses was 0.63%.The proportions of irrational medical orders in January-April 2018 and July-December 2018 were 0.92% and 0.37%,respectively.The difference was statistically significant (P<0.01),and the statistics of the top 4 irrational medical orders as the type of solvent,the amount of solvent,the dose of administration,and the order of administration were 0.26%,0.22%,0.18%,and 0.11%,respectively.The ratios were reduced to 0.12%,0.07%,0.09%,and 0.04%,and the differences were statistically significant(P<0.01 or P<0.05). Conclusion Pharmacists participation in the practice of PIVAS anti-tumor drugs could improve the rational use of anti-tumor drugs,ensure more accurate and effective pharmacy services,and promote the rational application of clinical anti-tumor drugs.
Jing AN,Jiangling WAN,Xiangliang YANG,Zifu LI. Progress of Enzyme Responsive Nanomedicine. 医药导报, 2020,39(9): 1240-1251.
Enzyme responsive nanomedicine is a kind of nano drug delivery system that changes its physical and chemical properties by endogenous enzyme.It can control the delivery and release of lipophilic drugs,proteins and genes,upgrade their water solubility,reduce their toxic and side effects,and increase their circulation time.Enzyme responsive nanomedicine can be applied in chemotherapy,gene therapy,photothermal therapy and photodynamic therapy for cancer treatment.This unique stimulus-response function is widely used in drug delivery,disease diagnosis and biomedical imaging.Herein,research progress of enzyme responsive nanomedicine is summarized,and the challenges and future development of enzyme responsive nanomedicine are discussed.
Haowen ZENG,Xiangliang YANG,Zifu LI. Advances in Mechano-nanooncology. 医药导报, 2020,39(9): 1252-1257.
With the rapid development of nanotechnology,novel nanoprobes have revealed the evolution of tumor mechano-microenvironment from tissue,cell and molecule levels; and some new nanooperators have achieved tumor killing or improved the efficacy of cancer therapy by intervening tumor mechano-microenvironment or cancer cell mechanics.The application of nanotechnology in tumor mechanobiology has fostered a new research hotspot,namely mechano-nanooncology.In this review, the authors attempt to define the term mechano-nanooncology and summarize the latest advances in leveraging mechano-nanoprobes and mechano-nanooperators for the study of tumor mechanobiology.Finally,the authors discuss current challenges of mechano-nanooncology and look forward to its future development.
ZHU Xiali,LI Linghua,WANG Shasha,BA Yanyan,JIA Jongyan. Preparation and Characterization of Near-infrared Light Responsive Doxorubicin Hydrochloride Liposomes. 医药导报, 2020,39(8): 1121-1124.
Objective To prepare and characterize a novel liposome which could be used for targeted synergistic chemo-photothermal cancer therapy. Methods Hydrophilic nano copper sulfide(PVP/CuS)was chosen as the near infrared photothermal agent, and doxorubicin hydrochloride(DOX)was used as the model chemo-therapeutic agent. DOX-PVP/CuS-Lip was successfully prepared by the membrane dispersion method. The zeta potential and particle size of DOX-PVP/CuS-Lip were determined by using Darwin laser particle size analyzer. The morphology was observed by TEM. The encapsulation efficiency was determined by the ultrafiltration centrifugation method. The characteristics of photothermal conversion were measured under near-infrared irradiation. And dialysis method was used for in vitro drug release test. Results DOX-PVP/CuS-Lip was spherical and uniform in size. The average particle size and zeta potential were 200.9 nm(PDI=0.43)and (-16.0±0.9) mV, respectively. The encapsulation efficiency and drug loading ratio were (91.0±2.0)% and (11.02±0.2)%, respectively. DOX-PVP/CuS-Lip had obvious photothermal conversion effect under near-infrared irradiation at 808 nm in a time-dependent manner. The in vitro drug release test showed that the formulation had obvious sustained release characteristics compared with DOX solution, and the release rate at 45 ℃ was significantly higher than that at 37 ℃. Conclusion The preparation process of DOX-PVP/CuS-Lip was stable and feasible. And the prepared DOX-PVP/CuS-Lip had obvious photo-thermal conversion efficiency and temperature dependent drug release characteristics.
YUAN Shumin,ZHANG Miao,WANG Zibing. Research Progress of Immune Checkpoint Inhibitors Combined with Other Treatments in Tumor. 医药导报, 2020,39(8): 1073-1078.
In recent years, immune checkpoint inhibitor represented by anti-PD-1, PD-L1 and CTLA-4 antibodies have been widely used in clinical tumor treatments. However, the overall efficacy of immunotherapy alone is low. To improve the efficacy, researchers try to combine it with other tumor treatment drugs/methods. This article mainly discusses the progress of immune checkpoint inhibitors combined with tumor vaccines, oncolytic viruses, modified immune cell therapies, and small molecule targeted therapies.
WEI Xiaoting,SI Lu. Tumor Immunotherapy in Combination with Immunotherapy for Tumor Treatment. 医药导报, 2020,39(8): 1063-1067.
In recent years, immunotherapies represented by immune checkpoint inhibitors have shown significant clinical efficacy in anti-tumor therapy, but some patients still cannot achieve the response. In order to improve the effect of immunotherapy and further expand the beneficiary population, a number of studies have been launched for the exploration of combined immunotherapies, including immuno-chemotherapy, targeted-immunotherapy, immuno-immunotherapy,etc. This paper summarizes the current clinical trials of immunotherapy in combination, and discusses the synergistic mechanism, curative effect, and application prospects of combined medication.
ZHAO Jing,SU Chunxia. Current Status and Future Direction of the Combination of Immunotherapy and Chemotherapy in Cancer. 医药导报, 2020,39(8): 1084-1088.
Chemotherapy can activate the immune response by directly stimulating the innate immune response and acquired immune cells, blocking the immunosuppressive pathways that promote tumor progression, improving the immunogenicity of tumor cells, or enhancing the sensitivity of immune response mechanism.Chemotherapy can also enhance the anti-tumor effect of immunotherapy, further improve the remission rate, and expand the beneficiary population of immunotherapy. The adverse reactions of the combined treatment can also be controlled. This article reviews the progress of the combination of immunotherapy and chemotherapy, the ongoing clinical research of immunochemotherapy, and discusses the existing problems and future directionof the combination.
XIONG Jiangmei,CHEN Liyuan,MA Yani,WU Hui. Choice of Infusion and Compatibility Order of Antitumor Drugs. 医药导报, 2020,39(6): 846-849.
Objective To provide the drug safety of antitumor drugs in clinical use. Methods Literatures were searched to summarize the stability problems and current situation of antitumor drugs in infusion selection and combination order. Results A total of 36 literatures ware searched. For different antitumor drugs,the infusion matrix of intravenous injection and the order of combined drugs would affect drug stability and safety. Conclusion In the process of using antitumor drugs,the selection of infusion matrix and the order of drug use should be paid attention to in the combination therapy.
Meiling GAO,Qiang CAI,Chen MENG,Qing LI,Xiancheng XU. Effect of General Anesthesia Combined with Lumbar Quadratus Block on Perioperative Analgesic Effect and T Lymphocytes in Patients Underwent Gynecologic Tumor Surgery. 医药导报, 2020,39(5): 654-657.
Objective To investigate effect of general anesthesia combined with lumbar quadratus block on perioperative analgesic effect and T lymphocytes in patients underwent gynecologic tumor surgery. Methods The eighty patients scheduled for gynecologic oncologic radical operation(ovarian cancer, cervical cancer) were enrolled in and randomly divided into general anesthesia combined QLB group(Group A, n=40) and single general anesthesia group (Group B, n=40). Correspondingly, the dosage of sufentanil used in the operation, VAS scores in resting state at 1 h (t0), 6 h (t1), 24 h (t2), 48 h (t3) and amount of remedial parecoxib sodium for injection were recorded. The level of C
MA Congjian,GAO Jianmei,KONG Hao,XU Yingshu. Research Progress of Pharmacological Effects of Phlorizin. 医药导报, 2020,39(3): 360-364.
Phlorizin is a major active component of Lithocarpus polystachyus Rehd,which is a kind of Chinese folkloric medicine. Accumulating evidence demonstrate that phlorizin exhibits multiple pharmacological effects including anti-oxidative effect,hypoglycemic effect, anti-inflammation, anti-tumor effect and anti-ischemia stroke.Based on domestic and foreign research reports,the pharmacological effects and its underlying molecular mechanisms of phlorizin were reviewed in this article.It will provide clue and evidence for research and development of phlorizin.
OU Wuling,CAI Qian,HU Sheng,DONG Shuang. Clinical Research Advances in Immunotherapy for Urogenital Tumor. 医药导报, 2020,39(10): 1384-1389.
The advent of immunotherapy has led to significant changes in the treatment landscape of urogenital tumors.Currently, a number of vaccines and immunosuppressive checkpoint inhibitors, such as drugs targeting the programmed death 1 (PD-1), and cytotoxic T-lymphocyte associated antigen (CTLA-4), have been approved for the second-line treatment of a variety of urogenital tumors, including prostate cancer, renal cell carcinoma, and urothelial carcinoma.In addition, there are many ongoing clinical trials aiming at exploring the combined use of immunotherapy and other types of drugs, and biomarkers for predicting the efficacy of tumor immunotherapy.And the role of immune checkpoint inhibitors in first-line and adjuvant treatment were also investigated so as to further improve the effectiveness and accuracy of immunotherapy and expand the beneficiary population.In this review, we summarize the clinical application of immunotherapy in urogenital system tumors, including three different types of urogenital tumors: prostate cancer, renal cancer and urothelial cancer.In addition, perspectives on the future use of checkpoint inhibitors are discussed, including the potential use in combination with other agents, and the identification of biomarkers to guide patient selection and individualization of therapy.
YUAN Xiaomei,GU Qing,LIU Li,WANG Wenyan. Mechanism of Tumor Necrosis Factor Superfamily 14 on Inflammation and Lipid Metabolism. 医药导报, 2020,39(1): 26-32.
Objective To explore the role of tumor necrosis factor superfamily member 14(LIGHT) in lipid metabolism, and to provide references for clinical treatment of hyperlipidemia-related diseases. Methods A total of 32 patients with coronary heart disease took part in the trial, including 16 patients in the unstable angina group and 16 patients in the stable angina group.Sixteen healthy people served as the control group.The expression of LIGHT in patients with coronary heart disease at different stages was examined.The expression of lipid metabolism-related enzymes and inflammation-related proteins in oxidized low density lipoprotein(oxLDL)-induced mononuclear macrophages(THP-1) was observed. Results The expression level of LIGHT in patients with coronary heart disease was significantly higher than that in healthy people(P<0.05).LIGHT enhanced the expression of scavenger receptor(SR-A), acetyl-CoA acetyltransferase 1(ACAT1), adipose gene(SREBP-1c, ACS),interleukin-6(IL-6), human monocyte chemotaxis protein-1(MCP-1), and nitric oxide synthase(iNOS)(P<0.05).These effects could be blocked by the lymphotoxin beta receptor(LTβR-Ig).The NF-κB translocation inhibitor SN50 significantly inhibited the expression of nuclear transcription factors(NF)-κB, p65, IL-6 and adipose genes(P<0.05). Conclusion LIGHT promotes inflammatory response and lipid accumulation by activating NF-κB signaling pathway, which providing a new potential target for the treatment of hyperlipidemia-related diseases.
联系客服
